Stayble presents at EUROSPINE Annual Meeting 2020

Stayble Therapeutics today announced that Professor Anders Lehmann, VP Development, will give a talk entitled ”Sclerosation of the intervertebral disc using lactic acid in patients with discogenic chronic low back pain: results from a phase 1b trial” at the EuroSpine Annual Meeting. The conference will be held virtually on October 6-9, 2020.

Anders Lehmann, VP Development of Stayble, comments: "The EUROSPINE Annual Meeting is one of the most important international scientific conferences in back-related research. It is essential for Stayble to participate in these conferences to present our research and discuss it with the international expertise. Only 7 percent of the submitted contributions were selected for oral presentations at this conference, which attests to the great interest shown in our novel and innovative concept."

The abstract can be found here. The title reads: 34. Sclerosation of the intervertebral disc (ivd) using lactic acid (la) in patients with discogenic chronic low back pain: results from a phase 1b trial.

Read more at www.eurospinemeeting.org

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development, and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se